

chain nodes :

1 2 3 4 5 6 7 15 16 17 24 25 42 45

ring nodes :

8 9 10 11 12 13 18 19 20 21 22 23 26 27 28 29 30 31 32 33 34 35 36
37

chain bonds :

1-2 1-4 1-45 3-16 4-5 4-15 5-6 6-7 7-8 15-42 17-18 24-25 25-26

ring bonds :

8-9 8-13 9-10 10-11 11-12 12-13 18-19 18-23 19-20 20-21 21-22 22-23 26-27
26-31 27-28 28-29 29-30 30-31 32-33 32-37 33-34 34-35 35-36 36-37

exact/norm bonds :

1-2 1-45 4-5 5-6 15-42 17-18

exact bonds :

1-4 3-16 4-15 6-7 7-8 24-25 25-26

normalized bonds :

8-9 8-13 9-10 10-11 11-12 12-13 18-19 18-23 19-20 20-21 21-22 22-23 26-27
26-31 27-28 28-29 29-30 30-31 32-33 32-37 33-34 34-35 35-36 36-37

G1:[*1],[*2],[*3]

G2:OH,[*4]

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:CLASS 25:CLASS 26:Atom 27:Atom 28:Atom 29:Atom
30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 42:CLASS
45:CLASS

Element Count :

Node 7: Limited
C,C6

=> d his

(FILE 'HOME' ENTERED AT 07:15:23 ON 18 NOV 2004)

FILE 'REGISTRY' ENTERED AT 07:15:28 ON 18 NOV 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FUL
L4 STRUCTURE UPLOADED

=> d l1


L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>





↖ L1

Structure attributes must be viewed using STN Express query preparation.

=>

=> d bib abs hitstr 40-42

L10 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:66723 CAPLUS
DN 128:188290
TI Highly Selective and Orally Active Inhibitors of Type IV Collagenase
(MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives
AU Tamura, Yoshinori; Watanabe, Fumihiko; Nakatani, Takuji; Yasui, Ken; Fuji,
Masahiro; Komurasaki, Tadafumi; Tsuzuki, Hiroshige; Maekawa, Ryuji;
Yoshioka, Takayuki; Kawada, Kenji; Sugita, Kenji; Ohtani, Mitsuaki
CS Shionogi Research Laboratories, Shionogi Co. Ltd., Osaka, 553, Japan
SO Journal of Medicinal Chemistry (1998), 41(4), 640-649
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
GI



AB Various N-sulfonylamino acid derivs., e.g. I (R1 = PhCH2, X = bond, Y = SO2, CO, Z = CONHOH, CO2H; R1 = indol-3-ylmethyl, X = bond, Y = SO2, Z = CONHOH, CO2H; R1 = Me2CH, X = O, Y = SO2, Z = CONHOH, CO2H) and II (R2 = indol-3-ylmethyl, R5 = H, OMe-4, OMe-3, A = CH:CH, X = bond; R2 = indol-3-ylmethyl, R5 = Me-4, A = S, X = bond; R2 = CHMe2, R5 = OMe-4, SMe-4, A = CH:CH, X = bond; R2 = CHMe2, R5 = OMe-4, A = S, X = bond; R2 = indol-3-ylmethyl, R5 = H, Me-4, CO2H-4, A = CH:CH, X = C.tplbond.C; R2 = indol-3-ylmethyl, R5 = NO2-2, NO2-4, Me-4, A = S, X = C.tplbond.C; R2 = CHMe2, R5 = Me-4, A = CH:CH, S, X = C.tplbond.C; R2 = CH2Ph, R5 = OMe-4, A = CH:CH, S, X = C.tplbond.C), were synthesized and evaluated for their in vitro and in vivo activities to inhibit type IV collagenase (MMP-9 and MMP-2). When the amino acid residue and the sulfonamide moiety were modified, their inhibitory activities were greatly affected by the structure of the sulfonamide moiety. A series of aryl sulfonamide derivs. containing biaryl, tetrazole, amide, and triple bond were found to be potent and highly selective inhibitors of MMP-9 and MMP-2. In addition, these compds. were orally active in animal models of tumor growth and metastasis. These results revealed the potential of the N-sulfonylamino acid derivs. as a new type of candidate drug for the treatment of cancer.

IT 140645-36-9P 193807-58-8P 193808-50-3P
193808-54-7P 193808-61-6P 203639-56-9P
203639-78-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-sulfonylamino acid derivs. as orally active type IV collagenase inhibitors)

RN 140645-36-9 CAPLUS

CN D-Tryptophan, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193807-58-8 CAPLUS

CN D-Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193808-50-3 CAPLUS

CN D-Valine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193808-54-7 CAPLUS


CN D-Phenylalanine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 193808-61-6 CAPLUS
CN D-Valine, N-[[4'-(methylthio)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 203639-56-9 CAPLUS
CN D-Tryptophan, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 203639-78-5 CAPLUS
CN D-Tryptophan, N-[(3'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 193810-34-3P 203639-55-8P 203639-77-4P
203640-17-9P 203640-18-0P 203640-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-sulfonylamino acid derivs. as orally active type IV
collagenase inhibitors)

RN 193810-34-3 CAPLUS

CN D-Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)-, phenylmethyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 203639-55-8 CAPLUS

CN D-Tryptophan, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Abs


Absolute stereochemistry. Rotation (+).



RN 203639-77-4 CAPLUS

CN D-Tryptophan, N-[(3'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 203640-17-9 CAPLUS

CN D-Valine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 203640-18-0 CAPLUS

CN D-Valine, N-[[4'-(methylthio)[1,1'-biphenyl]-4-yl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 203640-19-1 CAPLUS

CN D-Phenylalanine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:776147 CAPLUS

DN 128:48054

TI Biphenylsulfonamide matrix metalloproteinase inhibitors

IN O'Brien, Patrick Michael; Sliskovic, Drago Robert

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 29 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9744315	A1	19971127	WO 1997-US6801	19970424
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2253342	AA	19971127	CA 1997-2253342	19970424
	AU 9726803	A1	19971209	AU 1997-26803	19970424
	AU 713286	B2	19991125		
	EP 901466	A1	19990317	EP 1997-918788	19970424
	EP 901466	B1	20011031		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	CN 1219166	A	19990609	CN 1997-194719	19970424
	CN 1077885	B	20020116		
	BR 9710841	A	19990817	BR 1997-10841	19970424
	NZ 332711	A	20000623	NZ 1997-332711	19970424
	JP 2000511175	T2	20000829	JP 1997-542377	19970424
	AT 207891	E	20011115	AT 1997-918788	19970424
	ES 2167733	T3	20020516	ES 1997-918788	19970424
	SK 282863	B6	20021203	SK 1998-1577	19970424
	EE 3965	B1	20030217	EE 1998-397	19970424
	PL 186416	B1	20040130	PL 1997-329929	19970424
	CZ 294063	B6	20040915	CZ 1998-3668	19970424
	ZA 9704223	A	19971210	ZA 1997-4223	19970515
	BG 63940	B1	20030731	BG 1998-102918	19981112
	NO 9805326	A	19990114	NO 1998-5326	19981116
	KR 2000011095	A	20000225	KR 1998-709253	19981116
	HK 1019585	A1	20020531	HK 1999-104791	19991027
PRAI	US 1996-17460P	P	19960517		
	WO 1997-US6801	W	19970424		
OS	MARPAT 128:48054				
GI					



AB Title compds. I [R = H, halo; R1 = alkyl, halo, NO2, amino, aminoalkyl, cyano, alkoxy, alkoxy carbonyl, etc.; R2 = H, (un)substituted alkyl; and R3 = OH, alkoxy, or NHOH], are useful for inhibiting matrix **metalloproteinase** enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues. For instance, 4-BrC6H4Ph underwent 4'-sulfonation (79%), conversion of the resultant sulfonic acid to the sulfonyl chloride (69%), sulfonamidation with H-Val-OtBu.HCl (60%), and deprotection of the ester (96%), to give

title compound II. In an in vitro test for inhibition of the hydrolysis of thiopeptolide by collagenase or gelatinase B, II gave IC₅₀ values of 3.24 and 8.34 μ M, resp.

IT **199850-89-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of biphenylsulfonamides as matrix

metalloproteinase inhibitors)

RN 199850-89-0 CAPLUS

CN L-Valine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **199850-87-8P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of biphenylsulfonamides as matrix **metalloproteinase** inhibitors)

RN 199850-87-8 CAPLUS

CN L-Valine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **199850-67-4P 199850-68-5P 199850-69-6P**

199850-70-9P 199850-71-0P 199850-72-1P

199850-73-2P 199850-74-3P 199850-75-4P

199850-76-5P 199850-77-6P 199850-79-8P

199850-80-1P 199850-81-2P 199850-82-3P

199850-83-4P 199850-84-5P 199850-85-6P

199850-86-7P 199850-90-3P 199850-91-4P

199850-92-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenylsulfonamides as matrix **metalloproteinase**
inhibitors)

RN 199850-67-4 CAPLUS

CN L-Valine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 199850-68-5 CAPLUS

CN L-Valine, N-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 199850-69-6 CAPLUS

CN L-Valine, N-[(4'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 199850-70-9 CAPLUS

CN L-Valine, N-[(4'-amino[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 199850-71-0 CAPLUS

CN L-Valine, N-[(4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-72-1 CAPLUS

CN L-Valine, N-[(3',4'-dibromo[1,1'-biphenyl]-4-yl)sulfonyl]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 199850-73-2 CAPLUS

CN L-Valine, N-[(3'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-74-3 CAPLUS

CN L-Valine, N-[(4'-bromo-2'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-75-4 CAPLUS

CN D-Valine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-76-5 CAPLUS

CN L-Phenylalanine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-77-6 CAPLUS

CN L-Phenylalanine, N-[[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-79-8 CAPLUS

CN L-Alanine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-80-1 CAPLUS

CN L-Leucine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-81-2 CAPLUS

CN L-Valine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-82-3 CAPLUS

CN L-Valine, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-83-4 CAPLUS

CN L-Valine, N-[(3'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-84-5 CAPLUS

CN L-Valine, N-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-85-6 CAPLUS

CN L-Valine, N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-86-7 CAPLUS

CN L-Valine, N-[(4'-formyl[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-90-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[[(1S)-1-carboxy-2-methylpropyl]amino]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-91-4 CAPLUS

CN L-Valine, N-[[4'-(hydroxymethyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 199850-92-5 CAPLUS

CN L-Valine, N-[[4'-(aminomethyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:513624 CAPLUS

DN 127:162119

TI Preparation of N-sulfonylamino acid derivatives as
metalloproteinase inhibitors

IN Watanabe, Fumihiko; Tsuzuki, Hiroshige; Ohtani, Mitsuaki

PA Shionogi and Co., Ltd., Japan

SO PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9727174	A1	19970731	WO 1997-JP126	19970122
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2242416	AA	19970731	CA 1997-2242416	19970122
	AU 9713195	A1	19970820	AU 1997-13195	19970122
	AU 715764	B2	20000210		
	CN 1214041	A	19990414	CN 1997-193226	19970122
	BR 9707010	A	19990720	BR 1997-7010	19970122
	EP 950656	A1	19991020	EP 1997-900747	19970122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NZ 325939	A	20000623	NZ 1997-325939	19970122
	JP 2001316254	A2	20011113	JP 2001-69135	19970122
	SK 282995	B6	20030109	SK 1998-984	19970122
	RU 2198656	C2	20030220	RU 1998-115659	19970122
	TW 575547	B	20040211	TW 1997-86100862	19970127
	NO 9803376	A	19980914	NO 1998-3376	19980722
	US 6150394	A	20001121	US 1998-120378	19980722
	US 6207698	B1	20010327	US 1998-120197	19980722
	US 6235768	B1	20010522	US 1999-307818	19990510
	AU 738793	B2	20010927	AU 2000-30222	20000501
	US 6441021	B1	20020827	US 2000-710904	20001114
	US 2003139379	A1	20030724	US 2002-188115	20020703
	US 2003225043	A1	20031204	US 2002-290245	20021108
PRAI	JP 1996-30082	A	19960123		
	JP 1996-213555	A	19960813		
	JP 1997-526728	A3	19970122		
	WO 1997-JP126	W	19970122		
	US 1998-120197	A3	19980722		
	US 1998-120383	A1	19980722		

US 2000-710094
OS MARPAT 127:162119
GI

B3 20001113



AB The title compds. R5R4R3SO2NR2CHR1COY [R1 = (un)substituted alkyl, aryl, aralkyl, heteroaryl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = single bond, (un)substituted arylene, etc.; R4 = single bond, CH:CH, C.tplbond.C, CO, CONH, N:N, NHCONH, NHCO, O, S, SO2NH, etc.; R5 = (un)substituted alkyl, cycloalkyl, etc.; Y = NHOH, OH; a proviso is given] are prepared The title compound (R)-I in vitro showed IC50 of 3.95 μ M against MMP-9 (gelatinase B).


IT 193807-58-8P 193807-98-6P 193807-99-7P
193808-00-3P 193808-01-4P 193808-03-6P
193808-04-7P 193808-05-8P 193808-07-0P
193808-08-1P 193808-09-2P 193808-10-5P
193808-11-6P 193808-12-7P 193808-13-8P
193808-15-0P 193808-17-2P 193808-18-3P
193808-19-4P 193808-20-7P 193808-21-8P
193808-23-0P 193808-25-2P 193808-27-4P
193808-29-6P 193808-32-1P 193808-35-4P
193808-37-6P 193808-39-8P 193808-41-2P
193808-44-5P 193808-46-7P 193808-49-0P
193808-50-3P 193808-51-4P 193808-52-5P
193808-54-7P 193808-56-9P 193808-57-0P
193808-58-1P 193808-60-5P 193808-61-6P
193808-90-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylamino acid derivs. as **metalloproteinase** inhibitors)

RN 193807-58-8 CAPLUS


CN D-Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 193807-98-6 CAPLUS


CN 2-Thiazolepropanoic acid, α -([1,1'-biphenyl]-4-ylsulfonylamino)- (9CI) (CA INDEX NAME)



RN 193807-99-7 CAPLUS


CN 1H-Indole-2-propanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino] -
, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 193808-00-3 CAPLUS

CN 1H-Indole-2-propanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino] -
5-methoxy- (9CI) (CA INDEX NAME)



RN 193808-01-4 CAPLUS


CN 1-Naphthalenepropanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino] -
(9CI) (CA INDEX NAME)



RN 193808-03-6 CAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-04-7 CAPLUS


CN Butanoic acid, 2-[[([1,1'-biphenyl]-4-ylsulfonyl)amino]-4,4,4-trifluoro-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 193808-05-8 CAPLUS

CN Benzenebutanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 193808-07-0 CAPLUS


CN Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)-4-fluoro- (9CI) (CA INDEX NAME)



RN 193808-08-1 CAPLUS


CN Cyclohexanepropanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 193808-09-2 CAPLUS

CN 1H-Indole-2-propanoic acid, α -([(1,1'-biphenyl]-4-ylsulfonyl)amino)-1-methyl- (9CI) (CA INDEX NAME)




RN 193808-10-5 CAPLUS

CN 1H-Indole-2-propanoic acid, α -([(1,1'-biphenyl]-4-ylsulfonyl)amino)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 193808-11-6 CAPLUS

CN 1H-Indole-2-propanoic acid, α -([(1,1'-biphenyl]-4-ylsulfonyl)amino)-5-fluoro-1-methyl- (9CI) (CA INDEX NAME)




RN 193808-12-7 CAPLUS

CN 4-Pyridinepropanoic acid, α -([(1,1'-biphenyl]-4-ylsulfonyl)amino)- (9CI) (CA INDEX NAME)




RN 193808-13-8 CAPLUS

CN 2-Benzothiazolepropanoic acid, α -[([1,1'-biphenyl]-4-ylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 193808-15-0 CAPLUS


CN Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)- β -hydroxy- (9CI) (CA INDEX NAME)



RN 193808-17-2 CAPLUS

CN D-Aspartic acid, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-18-3 CAPLUS

CN D-Glutamic acid, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-19-4 CAPLUS

CN D-Serine, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-20-7 CAPLUS

CN D-Homoserine, N-([1,1'-biphenyl]-4-ylsulfonyl)-O-(phenylmethyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 193808-21-8 CAPLUS


CN D-Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)-4-carboxy- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 193808-23-0 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -([1,1'-biphenyl]-4-ylsulfonylamino)- (9CI) (CA INDEX NAME)




RN 193808-25-2 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -([1,1'-biphenyl]-4-ylsulfonylamino)-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 193808-27-4 CAPLUS


CN 1H-Benzimidazole-2-propanoic acid, α -[[[1,1'-biphenyl]-4-ylsulfonyl]amino]-1-(methoxycarbonyl)- (9CI) (CA INDEX NAME)



RN 193808-29-6 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -[[[4'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-32-1 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -[[[3'-methoxy[1,1'-biphenyl]-4-yl]sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-35-4 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -[[[4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-37-6 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -[[[4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-39-8 CAPLUS

CN 1H-Benzimidazole-2-propanoic acid, α -[[[4'-(methylthio)[1,1'-biphenyl]-4-yl)sulfonyl]amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-41-2 CAPLUS


CN D-Valine, N-([1,1'-biphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 193808-44-5 CAPLUS
 CN D-Valine, N-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 193808-46-7 CAPLUS
 CN D-Valine, N-([1,1':4',1''-terphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 193808-49-0 CAPLUS
 CN D-Valine, N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-50-3 CAPLUS

CN D-Valine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193808-51-4 CAPLUS

CN D-Valine, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-52-5 CAPLUS

CN D-Valine, N-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-54-7 CAPLUS

CN D-Phenylalanine, N-[(4'-methoxy[1,1'-biphenyl]-4-yl)sulfonyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 193808-56-9 CAPLUS

CN D-Phenylalanine, N-([1,1':4',1''-terphenyl]-4-ylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-57-0 CAPLUS

CN D-Phenylalanine, N-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-58-1 CAPLUS

CN D-Phenylalanine, N-[(4'-fluoro[1,1'-biphenyl]-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 193808-60-5 CAPLUS

CN D-Phenylalanine, N-[[4'-(methylthio)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 193808-61-6 CAPLUS

CN D-Valine, N-[[4'-(methylthio)[1,1'-biphenyl]-4-yl]sulfonyl]- (9CI) (CA
INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 193808-90-1 CAPLUS

CN D-Phenylalanine, N-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]sulfonyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 193810-34-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of sulfonylamino acid derivs. as **metalloproteinase** inhibitors)

RN 193810-34-3 CAPLUS

CN D-Phenylalanine, N-([1,1'-biphenyl]-4-ylsulfonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> d his

(FILE 'HOME' ENTERED AT 07:15:23 ON 18 NOV 2004)

FILE 'REGISTRY' ENTERED AT 07:15:28 ON 18 NOV 2004

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 0 S L1 FUL
L4 STRUCTURE UPLOADED
L5 STRUCTURE UPLOADED
L6 STRUCTURE UPLOADED
L7 946 S L6 FUL

FILE 'CAPLUS' ENTERED AT 07:19:14 ON 18 NOV 2004

L8 88 S L7
L9 23591 S METALLOPRO?
L10 42 S L9 AND L8

=> d 16

L6 HAS NO ANSWERS

L6 STR